New concepts on the role of human papillomavirus in cell cycle regulation.
暂无分享,去创建一个
[1] S. Syrjänen,et al. Papillomavirus Infections in Human Pathology , 2000 .
[2] A. Kristjuhan,et al. p53 Protein Is a Suppressor of Papillomavirus DNA Amplificational Replication , 1998, Journal of Virology.
[3] A. Ciechanover,et al. Basal and human papillomavirus E6 oncoprotein-induced degradation of Myc proteins by the ubiquitin pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[4] M. Scheffner,et al. The ubiquitin-protein ligase E6-associated protein (E6-AP) serves as its own substrate. , 1998, European journal of biochemistry.
[5] H. Drexler. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia–lymphoma cells , 1998, Leukemia.
[6] E. Auvinen,et al. The human papillomavirus type 16 E5-protein modulates ligand-dependent activation of the EGF receptor family in the human epithelial cell line HaCaT. , 1998, Experimental cell research.
[7] M Fujita,et al. Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[8] E. Flores,et al. Evidence for a switch in the mode of human papillomavirus type 16 DNA replication during the viral life cycle , 1997, Journal of virology.
[9] S. O. Smith,et al. Identification of amino acids in the transmembrane and juxtamembrane domains of the platelet-derived growth factor receptor required for productive interaction with the bovine papillomavirus E5 protein , 1997, Journal of virology.
[10] E. Auvinen,et al. Enhancement of EGF- and PMA-mediated MAP kinase activation in cells expressing the human papillomavirus type 16 E5 protein , 1997, Oncogene.
[11] D. Fishman,et al. Linking protein kinase C to cell-cycle control. , 1997, European journal of biochemistry.
[12] D. Pim,et al. Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth , 1997, Oncogene.
[13] L. Laimins,et al. Initiation of DNA synthesis by human papillomavirus E7 oncoproteins is resistant to p21-mediated inhibition of cyclin E-cdk2 activity , 1997, Journal of virology.
[14] H. Shirasawa,et al. Transactivation of Prothymosin α and c-mycPromoters by Human Papillomavirus Type 16 E6 Protein , 1997 .
[15] K. Vousden,et al. Perturbation of the p53 response by human papillomavirus type 16 E7 , 1997, Journal of virology.
[16] C. Gao,et al. Cyclins, cyclin‐dependent kinases and differentiation , 1997, BioEssays : news and reviews in molecular, cellular and developmental biology.
[17] S. Moreno,et al. Regulation of CDK/cyclin complexes during the cell cycle. , 1997, The international journal of biochemistry & cell biology.
[18] K. Münger,et al. Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein , 1997, Journal of virology.
[19] J. Brock,et al. HPV-Typen vom “high risk type” in oralen und laryngealen Papillomen und Leukoplakien* , 1997 .
[20] E. Villiers. Papillomavirus and HPV typing. , 1997 .
[21] G. Orth,et al. Commentary to part one , 1997 .
[22] N. Ramoz,et al. Human papillomaviruses: general features. , 1997, Clinics in dermatology.
[23] M. Yaniv,et al. Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis , 1997, The EMBO journal.
[24] L. Banks,et al. Repression of p53 transcriptional activity by the HPV E7 proteins. , 1997, Virology.
[25] C. Calef,et al. Heterogeneity of papillomaviruses. , 1996, Seminars in cancer biology.
[26] T. Wright,et al. Anogenital papillomavirus infection and neoplasia in immunodeficient women. , 1996, Obstetrics and gynecology clinics of North America.
[27] Y. Tsao,et al. Human papillomavirus type 11 and 16 E5 represses p21(WafI/SdiI/CipI) gene expression in fibroblasts and keratinocytes , 1996, Journal of virology.
[28] Harald zur Hausen,et al. Papillomavirus infections — a major cause of human cancers , 1996 .
[29] M. Kubbutat,et al. Role of E6 and E7 oncoproteins in HPV-induced anogenital malignancies , 1996 .
[30] Lawrence Da. Transforming growth factor-beta: a general review. , 1996, European cytokine network.
[31] H. Wang,et al. Kinetics of HPV11 DNA replication after infection of keratinocytes with virions. , 1996, Virus research.
[32] K. Wiman,et al. Abrogation of p53-induced G1 arrest by the HPV 16 E7 protein does not inhibit p53-induced apoptosis. , 1996, Oncogene.
[33] D. Pim,et al. HPV-16 E7 and adenovirus E1a complex formation with TATA box binding protein is enhanced by casein kinase II phosphorylation. , 1996, Oncogene.
[34] Y. Tsao,et al. Mutational analysis of human papillomavirus type 11 E5a oncoprotein , 1996, Journal of virology.
[35] B. Shan,et al. The molecular basis of E2F-1/DP-1-induced S-phase entry and apoptosis. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[36] M. Birrer,et al. The human papillomavirus type 16 E7 gene product interacts with and trans‐activates the AP1 family of transcription factors. , 1996, The EMBO journal.
[37] E. Androphy,et al. Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells , 1996, Journal of virology.
[38] M. Oren,et al. Specific loss of apoptotic but not cell‐cycle arrest function in a human tumor derived p53 mutant. , 1996, The EMBO journal.
[39] G. Matlashewski,et al. Effect of human papillomavirus type 16 oncogenes on MAP kinase activity , 1995, Journal of virology.
[40] S. Velasco-Miguel,et al. Induction of the growth inhibitor IGF-binding protein 3 by p53 , 1995, Nature.
[41] D. DiMaio,et al. Mutational analysis of the interaction between the bovine papillomavirus E5 transforming protein and the endogenous beta receptor for platelet-derived growth factor in mouse C127 cells , 1995, Journal of virology.
[42] R. Schlegel,et al. The human papilloma virus 16E6 gene sensitizes human mammary epithelial cells to apoptosis induced by DNA damage. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[43] E. Androphy,et al. Interaction of papillomavirus E6 oncoproteins with a putative calcium-binding protein. , 1995, Science.
[44] X. Graña,et al. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). , 1995, Oncogene.
[45] R. Schlegel,et al. E5 oncoprotein retained in the endoplasmic reticulum/cis Golgi still induces PDGF receptor autophosphorylation but does not transform cells. , 1995, The EMBO journal.
[46] L. Crawford,et al. Cell cycle-dependent disruption of E2F-p107 complexes by human papillomavirus type 16 E7. , 1995, The Journal of general virology.
[47] A. Burny,et al. Wild-type p53 down-regulates transcription from oncogenic human papillomavirus promoters through the epithelial specific enhancer. , 1995, Oncogene.
[48] D. DiMaio,et al. Ligand-independent activation of the platelet-derived growth factor beta receptor: requirements for bovine papillomavirus E5-induced mitogenic signaling , 1995, Molecular and cellular biology.
[49] D. McCance,et al. The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes , 1995, Journal of virology.
[50] D. Thorley-Lawson,et al. A novel form of Epstein-Barr virus latency in normal B cells in vivo , 1995, Cell.
[51] E. Androphy,et al. The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain. , 1995, Oncogene.
[52] John Calvin Reed,et al. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.
[53] D. Galloway,et al. The E6 protein of human papillomavirus type 16 functions as a transcriptional repressor in a mechanism independent of the tumor suppressor protein, p53. , 1994, Virology.
[54] D. Beach,et al. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. , 1994, The EMBO journal.
[55] A. Ciechanover. The ubiquitin-mediated proteolytic pathway: mechanisms of action and cellular physiology. , 1994, Biological chemistry Hoppe-Seyler.
[56] T. Crook,et al. Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function. , 1994, Oncogene.
[57] F. Carlotti,et al. Functional studies of E7 proteins from different HPV types. , 1994, Oncogene.
[58] L. Banks,et al. The human papillomavirus type 16 E5 gene cooperates with the E7 gene to stimulate proliferation of primary cells and increases viral gene expression. , 1994, Virology.
[59] J. Pines,et al. The cell cycle kinases. , 1994, Seminars in cancer biology.
[60] A. Lamond,et al. The endoplasmic reticulum calcium-binding protein of 55 kDa is a novel EF-hand protein retained in the endoplasmic reticulum by a carboxyl-terminal His-Asp-Glu-Leu motif. , 1994, The Journal of biological chemistry.
[61] F. Hoppe-Seyler,et al. Cellular control of human papillomavirus oncogene transcription , 1994, Molecular carcinogenesis.
[62] Miranda Thomas,et al. Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells. , 1994, Oncogene.
[63] M. Lechner,et al. Inhibition of p53 DNA binding by human papillomavirus E6 proteins , 1994, Journal of virology.
[64] D. DiMaio,et al. Specific interaction between the bovine papillomavirus E5 transforming protein and the beta receptor for platelet-derived growth factor in stably transformed and acutely transfected cells , 1994, Journal of virology.
[65] A. N. Meyer,et al. Cellular transformation by a transmembrane peptide: structural requirements for the bovine papillomavirus E5 oncoprotein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[66] T. Andrésson,et al. The E5 protein of HPV-6, but not HPV-16, associates efficiently with cellular growth factor receptors. , 1994, Virology.
[67] R. Elston,et al. Interaction of the E6 protein of human papillomavirus with cellular proteins. , 1994, Oncogene.
[68] Y. Moon,et al. Expression and localization of human papillomavirus type 16 E6 and E7 open reading frame proteins in human epidermal keratinocyte. , 1994, Yonsei medical journal.
[69] T. Crook,et al. Interaction of HPV E6 with p53 and associated proteins. , 1994, Biochemical Society transactions.
[70] S. Elledge,et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.
[71] J. Trent,et al. WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.
[72] M. Scheffner,et al. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53 , 1993, Cell.
[73] K. Helin,et al. Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation. , 1993, Genes & development.
[74] D. Lowy,et al. Transformation-specific interaction of the bovine papillomavirus E5 oncoprotein with the platelet-derived growth factor receptor transmembrane domain and the epidermal growth factor receptor cytoplasmic domain , 1993, Journal of virology.
[75] D. McCance,et al. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes , 1993, Journal of virology.
[76] K. Vousden. Interactions of human papillomavirus transforming proteins with the products of tumor suppressor genes , 1993 .
[77] Charles J. Sherr,et al. Mammalian G1 cyclins , 1993, Cell.
[78] T. Crook,et al. Human papillomavirus type 16 E7 associates with a histone H1 kinase and with p107 through sequences necessary for transformation , 1993, Journal of virology.
[79] D. W. Maher,et al. Alanine mutagenesis of conserved residues in the platelet-derived growth factor family: identification of residues necessary for dimerization and transformation. , 1993, Oncogene.
[80] V. Garsky,et al. Protein domains governing interactions between E2F, the retinoblastoma gene product, and human papillomavirus type 16 E7 protein , 1993, Molecular and cellular biology.
[81] M. Oren,et al. mdm2 expression is induced by wild type p53 activity. , 1993, The EMBO journal.
[82] B. Lin,et al. Tamoxifen stimulates human papillomavirus type 16 gene expression and cell proliferation in a cervical cancer cell line. , 1992, Cancer research.
[83] R. Schlegel,et al. The BPV‐1 E5 protein, the 16 kDa membrane pore‐forming protein and the PDGF receptor exist in a complex that is dependent on hydrophobic transmembrane interactions. , 1992, The EMBO journal.
[84] K. Münger,et al. Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins , 1992, Journal of virology.
[85] B. Vogelstein,et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.
[86] J. Minna,et al. Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins , 1992, Journal of virology.
[87] D. DiMaio,et al. Stable association between the bovine papillomavirus E5 transforming protein and activated platelet-derived growth factor receptor in transformed mouse cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[88] S. Weintraub,et al. Retinoblastoma protein switches the E2F site from positive to negative element , 1992, Nature.
[89] E. Androphy,et al. Mechanism of action of the papillomavirus E2 repressor: repression in the absence of DNA binding , 1992, Journal of virology.
[90] L. Donehower,et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.
[91] J. Nevins,et al. Analysis of trans activation by human papillomavirus type 16 E7 and adenovirus 12S E1A suggests a common mechanism , 1991, Journal of virology.
[92] M. Scheffner,et al. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. , 1991, The EMBO journal.
[93] D. DiMaio,et al. Tumorigenic transformation of murine keratinocytes by the E5 genes of bovine papillomavirus type 1 and human papillomavirus type 16 , 1991, Journal of virology.
[94] K. Vousden,et al. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation , 1991, Cell.
[95] P. Howley,et al. The papillomavirus E2 regulatory proteins. , 1991, The Journal of biological chemistry.
[96] D. DiMaio,et al. Biological properties of the deer papillomavirus E5 gene in mouse C127 cells: growth transformation, induction of DNA synthesis, and activation of the platelet-derived growth factor receptor , 1991, Journal of virology.
[97] D. Lowy,et al. The full-length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalize keratinocytes in culture , 1991, Journal of virology.
[98] G. Demers,et al. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells , 1991, Journal of virology.
[99] H. Bernard. Controls in the papillomavirus life cycle. , 1990, FEMS microbiology immunology.
[100] A. Levine,et al. Association of human papillomavirus types 16 and 18 E6 proteins with p53. , 1990, Science.
[101] R. Eisenman,et al. The E7 protein of human papillomavirus type 16 is phosphorylated by casein kinase II. , 1989, The New biologist.
[102] K. Münger,et al. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. , 1989, Science.
[103] M. Yaniv,et al. Study of the E2 gene product of the cottontail rabbit papillomavirus reveals a common mechanism of transactivation among papillomaviruses , 1988, Journal of virology.
[104] D. Galloway,et al. Identification of the E5 open reading frame of human papillomavirus type 16 , 1988, Journal of virology.
[105] D. McCance,et al. DNA sequence of the HPV-16 E5 ORF and the structural conservation of its encoded protein. , 1988, Virology.
[106] O'Connor Pm. Mammalian G1 and G2 phase checkpoints. , 1997 .
[107] L. Villa. Human papillomaviruses and cervical cancer. , 1997, Advances in cancer research.
[108] X. Graña,et al. pRB, p107 and p130 as transcriptional regulators: role in cell growth and differentiation. , 1997, Progress in cell cycle research.
[109] L. Laimins,et al. Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a complex with cdk2 and p107. , 1996, Virology.
[110] H. Hausen. Viruses In Human Tumors–Reminiscences And Perspectives , 1996 .
[111] A. Giordano,et al. Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. , 1995, Critical reviews in eukaryotic gene expression.
[112] A. Amerik,et al. The DOA pathway: studies on the functions and mechanisms of ubiquitin-dependent protein degradation in the yeast Saccharomyces cerevisiae. , 1995, Cold Spring Harbor symposia on quantitative biology.
[113] J. Sobczak-Thépot,et al. Cyclin A: function and expression during cell proliferation. , 1995, Progress in cell cycle research.
[114] G. Demers,et al. Cell cycle checkpoint control is bypassed by human papillomavirus oncogenes. , 1994, Cold Spring Harbor symposia on quantitative biology.
[115] P. Fuchs,et al. Anatomy, taxonomy and evolution of papillomaviruses. , 1994, Intervirology.
[116] L. Turek. The structure, function, and regulation of papillomaviral genes in infection and cervical cancer. , 1994, Advances in virus research.
[117] E. Villiers. Human Pathogenic Papillomavirus Types: An Update , 1994 .
[118] H. Hausen,et al. Human Pathogenic Papillomaviruses , 1994, Current Topics in Microbiology and Immunology.
[119] P. Fuchs,et al. Transcription of papillomavirus genomes. , 1994, Intervirology.
[120] M. Stanley,et al. Human papillomaviruses and cervical cancer : biology and immunology , 1994 .
[121] D. Mccance. Human papillomaviruses. , 1994, Infectious disease clinics of North America.
[122] T. Crook,et al. Human papillomavirus type 16 E7 regulates E2F and contributes to mitogenic signalling. , 1993, Oncogene.
[123] T. Hunt,et al. HPV16 E7 protein associates with the protein kinase p33CDK2 and cyclin A. , 1993, Oncogene.
[124] L. Banks,et al. The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus. , 1992, Oncogene.
[125] D. Pim,et al. Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor. , 1992, Oncogene.
[126] J. Gauthier,et al. The papillomavirus E2 protein: a factor with many talents. , 1991, Trends in biochemical sciences.
[127] V. Band,et al. Human papilloma virus DNAs immortalize normal human mammary epithelial cells and reduce their growth factor requirements. , 1990, Proceedings of the National Academy of Sciences of the United States of America.